The oncogenic capacity of LAMC2 has been well-documented in lung cancer, undifferentiated thyroid carcinoma, cholangiocarcinoma, laryngeal cancer, ovarian cancer and pancreatic cancer. This evidence concerns the gene LAMC2 and ovarian carcinoma.